Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.2-1 | Award Amount: 8.61M | Year: 2014
The aim of the iPaCT project is to address the unmet clinical need for an improved therapy of pancreatic cancer by developing a new integrated technology platform for image-guided thermal therapy. Yearly, 280000 new cases of pancreatic cancer are diagnosed worldwide. Being usually diagnosed late stage and without any efficient therapy available, basically all patients die with an average life expectancy of only a few months after diagnosis, leading to an overall low prevalence in society. Therefore, pancreatic cancer is a rare disease with an urgent clinical need for a new and improved therapeutic option. A potential breakthrough solution for the treatment of pancreatic cancer can be found in thermal therapies using high intensity focused ultrasound (HIFU) combined with local, temperature-triggered drug delivery. We propose a novel US-MR-HIFU system that integrates HIFU with two imaging modalities, i.e. Magnetic Resonance Imaging (MRI) and diagnostic Ultrasound (US) for image guidance of thermal ablation (T=60C) and/or hyperthermia (T=42-43C) of pancreatic tumours. For image-guided drug delivery, new temperature-sensitive nanocarriers will be developed that provide a high local dose of chemotherapeutic drug. Multimodal (molecular) imaging information, simultaneously acquired using the US-MR-HIFU platform, provides motion compensated temperature feedback as well as visualization of perfusion and drug uptake in the target tissue allowing personalized therapy. The consortium, including two innovative SMEs (Imasonic, Neagen), two hospitals (Klinikum der Universitt Mnchen and University Medical Center Utrecht), Eindhoven University of Technology and Philips (a medical device company), represents the total chain from technology development, preclinical testing to clinical translation guaranteeing a clear route for later clinical use and a route to market for the SMEs partners, leveraging the competencies and strengths of a leading global healthcare company.
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2007.3.6 | Award Amount: 4.33M | Year: 2008
The key objective of ULTRAsponder is to develop a novel telemetry technology for biomedical applications that will enable any kind of deeply implanted device (the transponder) to communicate and be powered wirelessly via acoustic waves with the external system (the control unit). The implanted transponder will include one or more sensors for monitoring a variety of parameters, such as temperature, pressure, or fluid flow. Local digital signal processing will allow the transponder to act smartly and transmit only significant data, reducing its power needs. As part of a network, several transponders will communicate and exchange information with the external control unit. The control unit will be placed on the patients skin, and it will control, energize and communicate through acoustic waves (ultrasonic) with the implanted transponders. Moreover, it will be used as a data logger, which relays the recorded data from the transponders network, towards the patients environment via cellular, plain telephone service (POTS) or IP based networks.The key innovations of ULTRAsponder will be the following: (i) development of a novel telemetry technique based on the backscattering principle to ensure efficient data communication through acoustic waves from the implanted transponder to the external control unit, (ii) wireless communication through acoustic waves from the control unit to the transponder, (iii) remote powering of the transponder through acoustic waves using a beam-forming technique to increase efficiency and hence to reduce charge time (iv) internal pre-treatment of the sensor measurements thanks to local massive and low power signal processing capabilities, (v) high flexibility and modularity of the transponder to be easily adaptable to any kind of sensor, (vi) test of the overall system in real environment for a particular application to measure physiological parameters, (vii) contribution to the standardization of body sensor networks using acoustic waves